Blood disorders
Lymphoma in Guangzhou
广州 淋巴瘤
16 hospitals in Guangzhou
Order: papers led on lymphoma, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for lymphoma: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Guangzhou may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 142 papers led
- 23 papers ledNo open trial led
- 19 papers ledNo open trial led
- 10 papers led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 6 papers ledNo open trial led
- 5 papers ledNo open trial led
- 4 papers led
- First Affiliated Hospital of Sun Yat-sen University中山大学附属第一医院International Medical Center, Nansha campus3 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 0 papers ledNo open trial led
Lymphoma in every city Guangzhou on the disease page, with the national map
open trials on lymphoma with a hospital in Guangzhou
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Guangzhou as lead sponsor or study site. 28 of them are led by a hospital in Guangzhou. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingSafety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2027-02
- Posted
- Registry
- NCT06902012
Age 18 years to Not stated (registered criteria)
Led by Zhujiang HospitalGuangzhou
- RecruitingA Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Phase
- Phase 4
- Started
- 2026-03
- Posted
- Registry
- NCT07218341
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Lanzhou, Nanchang, Shanghai, Tianjin, Urumqi, Xuzhou, Zhengzhou
- RecruitingA Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07409428
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 42 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Quanzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou, Zhengzhou
- RecruitingExploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07441993
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 11 listed hospitals as study sitesBeijing, Changchun, Changsha, Guangzhou, Jinan, Nanchang, Nantong, Tianjin, Wuhan, Zhengzhou
- RecruitingCelecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07494565
Age 18 years to 80 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- Phase
- Phase 1/Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07519772
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Shanghai, Zhengzhou
- RecruitingA Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Phase
- Phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07570017
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai
- RecruitingA Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.
- Phase
- Early phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07606937
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Tianjin
- RecruitingA Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2026-07
- Posted
- Registry
- NCT07661537
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Guangzhou
- RecruitingAn Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
- Phase
- Phase 1
- Started
- 2025-04
- Posted
- Registry
- NCT06487624
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Hangzhou, Yantai
- RecruitingA Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Phase
- Phase 1/Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06697184
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Suzhou
- RecruitingA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Phase
- Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT06717347
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanning, Nantong, Shanghai, Taiyuan, Tianjin, Wuhan, Xiamen
- RecruitingA Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06742996
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Wenzhou, Wuhan, Xuzhou, Zhengzhou
- RecruitingSafety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2025-01
- Posted
- Registry
- NCT06758713
Age 18 years to 75 years (registered criteria)
Led by Third Affiliated Hospital of Southern Medical UniversityGuangzhou
- RecruitingA Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2025-01
- Posted
- Registry
- NCT06820268
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shijiazhuang, Wuhan
- RecruitingClinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06829771
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Lanzhou, Luzhou, Quanzhou, Shanghai, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Zhengzhou
- RecruitingAcalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06846489
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingNewly-diagnosed Pediatric T-cell ALL Protocol
- Phase
- Phase 2/Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06855810
Age 1 month to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 13 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Qingdao, Shanghai, Tianjin, Wuhan
- RecruitingA Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
- Phase
- Phase 1/Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06855823
Age 18 years to 80 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT06911502
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Jinan, Wuhan
- RecruitingA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06943872
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hohhot, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Wuxi, Xiamen, Yangzhou
- RecruitingTucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
- Phase
- Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT06947967
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingDZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
- Phase
- Phase 1/Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07059650
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Taiyuan, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07082686
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingXinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma
- Phase
- Phase 2/Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07084662
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingGolidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07093710
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07124936
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shenyang, Suzhou, Taiyuan, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07154264
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nantong, Shenyang, Wuhan, Yichang, Zhengzhou
- RecruitingOrelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL
- Phase
- Phase 2/Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT07185373
Age 18 years to 75 years (registered criteria)
Led by Huashan Hospital; 11 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Jinan, Nanchang, Shanghai, Xi'an, Zhengzhou
- RecruitingPA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07188610
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Shanghai, Suzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingA Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07189065
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xiamen, Xuzhou, Zhengzhou
- RecruitingAn Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
- Phase
- Not given
- Started
- 2025-09
- Posted
- Registry
- NCT07200375
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan, Nanchang, Ningbo, Shanghai, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai, Zhengzhou
- RecruitingA Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
- Phase
- Phase 1
- Started
- 2024-01
- Posted
- Registry
- NCT06219356
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Taiyuan, Wuhan, Xiamen, Zhengzhou
- RecruitingIntratumoral CAN2109 in Subjects With Solid Tumors
- Phase
- Phase 1
- Started
- 2024-05
- Posted
- Registry
- NCT06332430
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06363994
Age 60 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
- Phase
- Phase 2/Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06378138
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Huai'an, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Yichang, Zhengzhou, Zunyi
- RecruitingStudy of AXT-1003 in Subjects With Advanced Malignant Tumors.
- Phase
- Phase 1
- Started
- 2024-09
- Posted
- Registry
- NCT06484985
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Shanghai
- RecruitingSelinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06517511
Age 18 years to 80 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteGuangzhou, Shanghai
- RecruitingEvaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06521255
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Tianjin, Urumqi, Wenzhou, Wuhan, Zhengzhou
- RecruitingA Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06566586
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Guangzhou, Harbin, Hohhot, Lanzhou, Luzhou, Nanchang, Nanning, Shanghai, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients
- Phase
- Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06569485
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingOrelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients(Rocket Trial)
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06647940
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Lanzhou, Shantou, Zhuhai
- RecruitingPhase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)
- Phase
- Phase 2
- Started
- 2024-01
- Posted
- Registry
- NCT06733051
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteBeijing, Guangzhou
- RecruitingSintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06848569
Age 1 year to 18 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT07234162
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingA Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2023-02
- Posted
- Registry
- NCT05800977
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai, Tianjin, Zhengzhou
- RecruitingPianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma
- Phase
- Phase 2
- Started
- 2023-10
- Posted
- Registry
- NCT05949931
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingEfficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06082102
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Dalian, Guangzhou, Hangzhou, Nanchang, Qingdao, Shanghai, Shenyang, Wuhan, Xi'an, Yantai, Zhengzhou
- RecruitingA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
- Phase
- Phase 3
- Started
- 2023-10
- Posted
- Registry
- NCT06084936
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou
- RecruitingA Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
- Phase
- Phase 1/Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06090539
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Nanchang
- RecruitingA Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06136559
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Taiyuan, Tianjin, Urumqi, Wuhan, Xuzhou, Zhengzhou
- RecruitingRCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma
- Phase
- N/A
- Started
- 2023-12
- Posted
- Registry
- NCT06190301
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Ophthalmic CenterGuangzhou
- RecruitingRelma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06876688
Age 18 years to Not stated (registered criteria)
Led by Ruijin Hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Wuhan, Zhengzhou
- RecruitingA Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Phase
- Phase 1
- Started
- 2022-03
- Posted
- Registry
- NCT05091424
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Nanchang, Tianjin
- RecruitingA Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Phase
- Phase 2/Phase 3
- Started
- 2022-01
- Posted
- Registry
- NCT05139017
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Luoyang, Nanchang, Shanghai, Wuhan, Zhengzhou
- RecruitingA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Phase
- Phase 3
- Started
- 2022-07
- Posted
- Registry
- NCT05254743
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Guangzhou, Haikou, Hangzhou, Hefei, Nanchang, Nanning, Shanghai, Tianjin, Urumqi, Wuhan
- RecruitingTreatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
- Phase
- Phase 1/Phase 2
- Started
- 2022-05
- Posted
- Registry
- NCT05294731
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Suzhou, Taiyuan, Wenzhou, Wuhan, Zhengzhou
- RecruitingEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Phase
- Phase 2
- Started
- 2021-04
- Posted
- Registry
- NCT04728893
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingOrelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
- Phase
- Phase 2
- Started
- 2021-08
- Posted
- Registry
- NCT04989621
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou
- RecruitingA Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma
- Phase
- Phase 1
- Started
- 2021-07
- Posted
- Registry
- NCT04993690
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou
- RecruitingA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2021-09
- Posted
- Registry
- NCT05006716
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Tianjin, Wenzhou, Yichang, Zhengzhou
- RecruitingStudy of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
- Phase
- Phase 2
- Started
- 2021-12
- Posted
- Registry
- NCT05147467
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesGuangzhou, Haikou, Hangzhou, Nanchang, Suzhou, Wuhan, Zhengzhou
- RecruitingA Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
- Phase
- Phase 1
- Started
- 2021-03
- Posted
- Registry
- NCT06189391
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Chengdu, Guangzhou, Jinan, Nanchang, Shanghai, Shijiazhuang, Tianjin, Xiamen, Zhengzhou
- RecruitingA Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)
- Phase
- Phase 3
- Started
- 2020-05
- Posted
- Registry
- NCT04365036
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingEvaluate the Safety and Clinical Activity of HH2853
- Phase
- Phase 1/Phase 2
- Started
- 2020-09
- Posted
- Registry
- NCT04390737
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou
- RecruitingStudy of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
- Phase
- Phase 1/Phase 2
- Started
- 2020-08
- Posted
- Registry
- NCT04494503
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan
- RecruitingPhase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
- Phase
- Phase 2
- Started
- 2020-10
- Posted
- Registry
- NCT04586478
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Wuhan, Zhengzhou
- RecruitingA Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Phase
- Phase 1
- Started
- 2018-04
- Posted
- Registry
- NCT03460977
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chengdu, Guangzhou, Nanjing, Wenzhou
- Not yet recruitingA Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
- Phase
- Phase 1
- Started
- 2026-08
- Posted
- Registry
- NCT06970496
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesGuangzhou, Nanchang, Shanghai, Wenzhou, Xi'an
- Not yet recruitingGlofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07231250
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingLisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study
- Phase
- Phase 1/Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07398638
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingSintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma
- Phase
- N/A
- Started
- 2026-06
- Posted
- Registry
- NCT07542912
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingA Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07574528
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingLisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07601607
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingAI-Assisted Optimization of Online Adaptive Radiotherapy for Gastric Lymphoma
- Phase
- N/A
- Started
- 2026-05
- Posted
- Registry
- NCT07609355
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingAdebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07615283
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingPirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07622784
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingRituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07654465
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingA First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07658352
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingA Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL)
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07676175
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Tianjin, Xi'an
- Not yet recruitingGolidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07753642
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingA Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07784101
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou
- Not yet recruitingA Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07818499
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Suzhou
- Not yet recruitingA Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07855016
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai
- Not yet recruitingOrelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07896590
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 40 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
- Not yet recruitingTafasitamab, Lenalidomide, Rituximab, and Orelabrutinib for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-12
- Posted
- Registry
- NCT07938619
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingHigh-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06646211
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingEfficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06757894
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingEvaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06845241
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Guangzhou, Nanchang, Tianjin, Zhengzhou
- Not yet recruitingZanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT06890585
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingObinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A
- Phase
- Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06961500
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingAssessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07032532
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Guangzhou
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Lung cancer | Pancreatic cancer | Breast cancer | Glioma | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Lymphoma | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Coronary heart disease | Congenital heart disease | Scoliosis | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Affiliated Brain Hospital of Guangzhou Medical University广州医科大学附属脑科医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Affiliated Cancer Hospital of Guangzhou Medical University广州医科大学附属肿瘤医院 | 291 open | 1 | 31 | 18 | 28 | none | 30 | 15 | none | none | none | 0 | none | 1 | 0 | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Affiliated Hospital of Southern China University of Technology华南理工大学医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Affiliated Hospital, Sun Yat-sen University中山大学附属口腔医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Air Force Hospital中国人民解放军南部战区空军医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Children Hospital广东省妇幼保健院 | none | none | none | none | none | none | 13 | none | none | none | none | 1 | none | 0 | 1 | none | none | none | none | none | 7 | none | none | none | none | none | none | none | none | none | none | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | 2 | none | none | none | none | none | none | none | |
| Children's Medical Center广州医科大学附属妇女儿童医疗中心 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | |
| Clifford Hospital | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Dermatology Hospital上海市皮肤病医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | 1 | none | none | none | none | none | none | |
| Dermatology Hospital, Southern Medical University南方医科大学皮肤病医院、广东省皮肤病医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | |
| Eighth People's Hospital of Guangzhou Affiliated to Guangzhou Medical College广州医科大学附属市八医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Fifth Affiliated Hospital of Guangzhou Medical University广州医科大学附属第五医院 | 1 | 5 | none | none | 22 | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Fifth Affiliated Hospital of Southern Medical University南方医科大学第五附属医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital of Guangdong Pharmaceutical University广东药科大学附属第一医院 | 4 | none | none | none | none | none | none | none | none | none | none | 0 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital of Guangzhou Medical University广州医科大学附属第一医院 | 6 | 3 | none | none | 18621 open | none | none | none | none | none | none | 0 | none | 1 | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | 0 | 0 | none | 21 | 3 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | 0 | none | none | none | none | |
| First Affiliated Hospital of Guangzhou University of Chinese Medicine广州中医药大学第一附属医院 | 2 | none | 32 | 12 | 35 | none | 4 | none | none | none | none | 2 | none | none | none | 2 | none | none | none | 7 | 0 | 0 | none | none | none | none | none | 6 | none | none | none | 4 | none | none | none | 1 | none | 4 | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital of Jinan University暨南大学附属第一医院 | 16 | 5 | 451 open | 21 | 59 | none | 57 | 30 | none | 0 | none | 9 | 1 | 2 | none | 5 | none | none | none | 5 | 2 | none | none | none | none | none | none | 4 | none | 2 | none | 7 | 6 | none | 0 | none | none | 1 | none | none | none | none | none | none | none | 1 | 0 | none | none | none | none | none | none | 2 | 2 | none | none | none | none | none | none | |
| First Affiliated Hospital of Sun Yat-sen University中山大学附属第一医院 | 143 open | 201 open | 2196 open | 52 | 71 | 39 | 491 open | 391 open | 5 | 1 | 0 | 33 | 92 open | 0 | 1 | 18 | 1 | none | 2 | 3 | 5 | none | none | none | none | 2 | none | 28 | 4 | 6 | 12 | 211 open | 61 open | 5 | 2 | 0 | 1 | 9 | none | 2 | 4 | 0 | 0 | 5 | 4 | 0 | 222 open | 0 | none | none | 1 | 0 | none | 1 | none | 0 | 0 | none | none | none | none | |
| Fuda Cancer Hospital广州复大肿瘤医院 | 0 | none | 0 | 0 | 0 | 0 | 0 | 0 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangdong Clifford Hospital广东祈福医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangdong Province Hospital for Occupational Disease Prevention and Treatment广东省职业病防治院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangdong Provincial Hospital of Chinese Medicine广东省中医院 | 5 | none | 25 | 12 | 41 | 6 | 501 open | 12 | none | none | none | 2 | 1 | 3 | 1 | none | none | none | none | none | 0 | none | none | none | none | 4 | none | 0 | none | none | none | 15 | 7 | none | 0 | none | none | 2 | 1 | 4 | none | none | none | none | none | none | 6 | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | |
| Guangdong Provincial People's Hospital广东省人民医院 | 14 | 19 | 541 open | 211 open | 23619 open | 441 open | 9610 open | 43 | 1 | 2 | 1 | 11 | 1 | 0 | none | 3 | 1 | none | none | 23 | 1 | none | none | none | none | 3 | 3 | 1 | none | none | none | 652 open | 80 | none | none | 0 | none | 2 | none | 1 | none | 1 | none | none | 1 | none | 81 open | none | none | none | 4 | 1 | none | none | none | none | none | none | none | none | none | |
| Guangdong Provincial Second Hospital广东省第二中医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangdong Second Provincial General Hospital广东省第二人民医院 | 3 | none | 16 | none | none | none | none | none | none | none | none | 2 | none | 1 | none | 31 open | none | none | 2 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 4 | none | none | 1 | none | 1 | none | none | none | 1 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangzhou Chest Hospital广州市胸科医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangzhou Dongsheng Hospital广州市东升医院(广州市老年病康复医院) | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangzhou Eighth People's Hospital广州市第八人民医院(嘉禾院区) | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | |
| Guangzhou First People's Hospital广州市第一人民医院 | 4 | none | 22 | 12 | none | 11 | 20 | none | none | none | none | 4 | 0 | 1 | none | 0 | none | 13 | none | 7 | 1 | none | none | 1 | 1 | none | none | none | none | none | none | none | none | none | 4 | 1 | none | 2 | none | none | none | none | none | 2 | none | none | 1 | 0 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Guangzhou General Hospital中国人民解放军南部战区总医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | 0 | 0 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangzhou Hospital广州市中西医结合医院 | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangzhou Orthopedics Hospital广州市正骨医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangzhou Panyu Central Hospital广州医科大学附属番禺中心医院 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangzhou Red Cross Hospital广州市红十字会医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | |
| Guangzhou Women and Children's Medical Center广州市妇女儿童医疗中心 | 2 | none | none | none | 5 | none | 161 open | 13 | 9 | 3 | none | 1 | 0 | 321 open | none | none | 21 open | none | none | none | 191 open | 0 | none | none | none | 1 | none | none | none | 2 | 19 | 7 | 34 | 2 | 3 | none | none | 1 | none | 0 | none | none | 1 | 2 | none | 2 | 0 | 1 | none | 1 | none | 0 | 11 | 7 | none | none | none | none | none | none | none | |
| Hexian Memorial Hospital广州市番禺区妇幼保健院 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | |
| Huadu Distinct People's Hospital广州市花都区人民医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Integrated Hospital, Southern Medical University南方医科大学中西医结合医院 | 7 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Nanfang Hospital南方医科大学南方医院 | 336 open | 84 open | 1277 open | 12812 open | 835 open | 8 | 832 open | 531 open | 0 | 0 | none | 6 | 2 | 2 | none | 3 | 8 | none | none | 19 | 21 | 9 | 1 | none | none | 3 | none | 1 | 6 | none | none | 13 | 1 | 0 | 7 | none | none | 5 | none | 6 | 1 | 2 | none | 0 | none | 0 | 51 open | none | none | none | 1 | none | 1 | 0 | none | none | 2 | none | none | none | none | |
| Panyu Hospital广州市番禺区中医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Second Affiliated Hospital of Guangzhou Medical University广州医科大学附属第二医院 | 4 | none | 3918 open | 41 open | 1315 open | 64 open | 84 open | 14 | none | none | none | 1 | none | 1 | none | 5 | 0 | none | none | 2 | 2 | 0 | none | none | none | 2 | none | none | none | none | none | none | 4 | none | 0 | none | none | 3 | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | |
| Sixth Affiliated Hospital of Guangzhou Medical University清远市人民医院 | 3 | none | none | none | none | none | none | 12 | none | none | none | 2 | none | none | none | none | none | none | none | none | 1 | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Sixth Affiliated Hospital of Sun Yat-sen University中山大学附属第六医院 | none | 0 | none | 455 open | none | 7 | 161 open | none | none | 0 | none | 1 | 3 | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | 4 | 1 | none | none | none | 1 | none | 0 | 1 | none | 0 | none | none | none | none | |
| Sun Yat-sen Memorial Hospital中山大学孙逸仙纪念医院 | 255 open | 102 open | 6610 open | 115 open | 362 open | 34 | 13548 open | 11 | 2 | none | none | 6 | 0 | 101 open | 2 | 1 | 4 | none | 4 | 7 | 6 | none | none | none | none | 01 open | 4 | none | none | none | none | 29 | 2 | 4 | none | none | 1 | none | none | 3 | none | none | none | none | 1 | none | 7 | none | none | 0 | 0 | 0 | none | none | none | none | none | none | none | none | none | |
| Sun Yat-sen University Cancer Center中山大学肿瘤防治中心 | 48357 open | 1378 open | 28118 open | 1034 open | 35732 open | 553 open | 22217 open | 621 open | 01 open | none | 0 | 191 open | 2 | 75 open | 31 open | 16 | 3 | none | 1 | 14225 open | 1 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Third Affiliated Hospital of Guangzhou Medical University广州医科大学附属第三医院 | 4 | none | none | none | none | 20 | none | none | none | none | none | 4 | none | 0 | none | none | none | none | none | none | 5 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | 1 | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | |
| Third Affiliated Hospital of Guangzhou University of Chinese Medicine广州中医药大学第三附属医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Third Affiliated Hospital of Southern Medical University南方医科大学第三附属医院 | 8 | none | none | none | none | none | none | none | none | none | none | 9 | none | none | 0 | 31 open | none | none | none | 21 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Third Affiliated Hospital of Sun Yat-sen University中山大学附属第三医院 | 10 | none | 1713 open | 15 | none | 6 | 19 | none | 1 | none | none | 2 | 0 | 1 | none | 4 | none | none | 1 | 6 | 0 | none | none | none | 1 | 392 open | none | 01 open | 3 | 0 | none | 9 | none | 4 | 22 | 2 | none | 1 | none | 2 | none | none | none | none | 0 | 1 | 0 | none | 0 | none | 2 | 1 | none | none | none | 0 | none | none | none | none | none | |
| Third People's Hospital, Guangzhou Medical University | none | none | none | none | 01 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Zhongshan Ophthalmic Center中山大学中山眼科中心 | none | none | none | none | none | none | none | none | none | 251 open | none | none | none | 0 | none | none | none | none | none | 41 open | none | none | none | none | none | 4 | none | none | none | none | none | none | 8 | 1 | none | none | none | none | none | none | none | none | none | none | 7 | none | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | |
| Zhujiang Hospital南方医科大学珠江医院 | 11 | 4 | 545 open | 10 | 691 open | 21 | 24 | 661 open | none | 1 | 1 | 9 | none | 6 | none | 23 open | 12 open | none | none | 101 open | 1 | none | none | none | none | none | none | none | none | none | none | 7 | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | 2 | none | none | none | none | none | none | 5 | none | none | none | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Guangzhou.
- Nasopharyngeal carcinoma 6
- Oesophageal squamous cell carcinoma 3
- Lung cancer 18621 open
- Osteosarcoma 0
- Neuroblastoma 1
- Lymphoma 1
- Congenital heart disease 2
- Anti-NMDA receptor encephalitis 0
- Takayasu arteritis 0
- Idiopathic pulmonary fibrosis 21
- Lymphangioleiomyomatosis 3
- Primary biliary cholangitis 1
- Familial adenomatous polyposis 0
- Nasopharyngeal carcinoma 16
- Oesophageal squamous cell carcinoma 5
- Hepatocellular carcinoma 451 open
- Stomach cancer 21
- Lung cancer 59
- Breast cancer 57
- Glioma 30
- Retinoblastoma 0
- Osteosarcoma 9
- Gastrointestinal stromal tumour 1
- Neuroblastoma 2
- Multiple myeloma 5
- Lymphoma 5
- Beta thalassaemia 2
- Myasthenia gravis 4
- Wilson disease 2
- Coronary heart disease 7
- Congenital heart disease 6
- Anti-NMDA receptor encephalitis 0
- Idiopathic pulmonary fibrosis 1
- Alport syndrome 1
- IgA nephropathy 0
- Hirschsprung disease 2
- Inherited epidermolysis bullosa 2
- Nasopharyngeal carcinoma 143 open
- Oesophageal squamous cell carcinoma 201 open
- Hepatocellular carcinoma 2196 open
- Stomach cancer 52
- Lung cancer 71
- Pancreatic cancer 39
- Breast cancer 491 open
- Glioma 391 open
- Hepatoblastoma 5
- Retinoblastoma 1
- Chordoma 0
- Osteosarcoma 33
- Gastrointestinal stromal tumour 92 open
- Neuroblastoma 0
- Ewing sarcoma 1
- Multiple myeloma 18
- B-cell acute lymphoblastic leukaemia 1
- Haemophagocytic lymphohistiocytosis 2
- Lymphoma 3
- Beta thalassaemia 5
- Neuromyelitis optica spectrum disorder 2
- Myasthenia gravis 28
- Moyamoya disease 4
- Wilson disease 6
- Biliary atresia 12
- Coronary heart disease 211 open
- Congenital heart disease 61 open
- Scoliosis 5
- Anti-NMDA receptor encephalitis 2
- Takayasu arteritis 0
- Hepatic echinococcosis 1
- Idiopathic pulmonary fibrosis 9
- Amyotrophic lateral sclerosis 2
- Spinal muscular atrophy 4
- Fabry disease 0
- Pompe disease 0
- Duchenne muscular dystrophy 5
- Behçet disease 4
- Alport syndrome 0
- IgA nephropathy 222 open
- Gaucher disease 0
- Primary biliary cholangitis 1
- Primary sclerosing cholangitis 0
- Hirschsprung disease 1
- Hereditary angioedema 0
- Familial adenomatous polyposis 0
- Nasopharyngeal carcinoma 5
- Hepatocellular carcinoma 25
- Stomach cancer 12
- Lung cancer 41
- Pancreatic cancer 6
- Breast cancer 501 open
- Glioma 12
- Osteosarcoma 2
- Gastrointestinal stromal tumour 1
- Neuroblastoma 3
- Ewing sarcoma 1
- Beta thalassaemia 0
- Neuromyelitis optica spectrum disorder 4
- Myasthenia gravis 0
- Coronary heart disease 15
- Congenital heart disease 7
- Anti-NMDA receptor encephalitis 0
- Idiopathic pulmonary fibrosis 2
- Lymphangioleiomyomatosis 1
- Amyotrophic lateral sclerosis 4
- IgA nephropathy 6
- Primary biliary cholangitis 2
- Nasopharyngeal carcinoma 14
- Oesophageal squamous cell carcinoma 19
- Hepatocellular carcinoma 541 open
- Stomach cancer 211 open
- Lung cancer 23619 open
- Pancreatic cancer 441 open
- Breast cancer 9610 open
- Glioma 43
- Hepatoblastoma 1
- Retinoblastoma 2
- Chordoma 1
- Osteosarcoma 11
- Gastrointestinal stromal tumour 1
- Neuroblastoma 0
- Multiple myeloma 3
- B-cell acute lymphoblastic leukaemia 1
- Lymphoma 23
- Beta thalassaemia 1
- Neuromyelitis optica spectrum disorder 3
- IgG4-related disease 3
- Myasthenia gravis 1
- Coronary heart disease 652 open
- Congenital heart disease 80
- Takayasu arteritis 0
- Idiopathic pulmonary fibrosis 2
- Amyotrophic lateral sclerosis 1
- Fabry disease 1
- Behçet disease 1
- IgA nephropathy 81 open
- Primary biliary cholangitis 4
- Primary sclerosing cholangitis 1
- Nasopharyngeal carcinoma 4
- Hepatocellular carcinoma 22
- Stomach cancer 12
- Pancreatic cancer 11
- Breast cancer 20
- Osteosarcoma 4
- Gastrointestinal stromal tumour 0
- Neuroblastoma 1
- Multiple myeloma 0
- Aplastic anaemia 13
- Lymphoma 7
- Beta thalassaemia 1
- Thrombotic thrombocytopenic purpura 1
- Fanconi anaemia 1
- Anti-NMDA receptor encephalitis 4
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 2
- Duchenne muscular dystrophy 2
- IgA nephropathy 1
- Gaucher disease 0
- Primary biliary cholangitis 0
- Nasopharyngeal carcinoma 2
- Lung cancer 5
- Breast cancer 161 open
- Glioma 13
- Hepatoblastoma 9
- Retinoblastoma 3
- Osteosarcoma 1
- Gastrointestinal stromal tumour 0
- Neuroblastoma 321 open
- B-cell acute lymphoblastic leukaemia 21 open
- Beta thalassaemia 191 open
- Haemophilia A 0
- Neuromyelitis optica spectrum disorder 1
- Wilson disease 2
- Biliary atresia 19
- Coronary heart disease 7
- Congenital heart disease 34
- Scoliosis 2
- Anti-NMDA receptor encephalitis 3
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 0
- Pompe disease 1
- Duchenne muscular dystrophy 2
- Alport syndrome 2
- IgA nephropathy 0
- Gaucher disease 1
- Osteogenesis imperfecta 1
- Primary sclerosing cholangitis 0
- Congenital diaphragmatic hernia 11
- Hirschsprung disease 7
- Nasopharyngeal carcinoma 336 open
- Oesophageal squamous cell carcinoma 84 open
- Hepatocellular carcinoma 1277 open
- Stomach cancer 12812 open
- Lung cancer 835 open
- Pancreatic cancer 8
- Breast cancer 832 open
- Glioma 531 open
- Hepatoblastoma 0
- Retinoblastoma 0
- Osteosarcoma 6
- Gastrointestinal stromal tumour 2
- Neuroblastoma 2
- Multiple myeloma 3
- B-cell acute lymphoblastic leukaemia 8
- Lymphoma 19
- Beta thalassaemia 21
- Haemophilia A 9
- Atypical haemolytic uraemic syndrome 1
- Neuromyelitis optica spectrum disorder 3
- Myasthenia gravis 1
- Moyamoya disease 6
- Coronary heart disease 13
- Congenital heart disease 1
- Scoliosis 0
- Anti-NMDA receptor encephalitis 7
- Idiopathic pulmonary fibrosis 5
- Amyotrophic lateral sclerosis 6
- Spinal muscular atrophy 1
- Fabry disease 2
- Duchenne muscular dystrophy 0
- Alport syndrome 0
- IgA nephropathy 51 open
- Primary biliary cholangitis 1
- Congenital diaphragmatic hernia 1
- Hirschsprung disease 0
- Familial adenomatous polyposis 2
- Nasopharyngeal carcinoma 4
- Hepatocellular carcinoma 3918 open
- Stomach cancer 41 open
- Lung cancer 1315 open
- Pancreatic cancer 64 open
- Breast cancer 84 open
- Glioma 14
- Osteosarcoma 1
- Neuroblastoma 1
- Multiple myeloma 5
- B-cell acute lymphoblastic leukaemia 0
- Lymphoma 2
- Beta thalassaemia 2
- Haemophilia A 0
- Neuromyelitis optica spectrum disorder 2
- Congenital heart disease 4
- Anti-NMDA receptor encephalitis 0
- Idiopathic pulmonary fibrosis 3
- IgA nephropathy 0
- Hereditary angioedema 0
- Oesophageal squamous cell carcinoma 0
- Stomach cancer 455 open
- Pancreatic cancer 7
- Breast cancer 161 open
- Retinoblastoma 0
- Osteosarcoma 1
- Gastrointestinal stromal tumour 3
- Beta thalassaemia 1
- Behçet disease 1
- IgA nephropathy 4
- Gaucher disease 1
- Primary sclerosing cholangitis 1
- Hirschsprung disease 0
- Inherited epidermolysis bullosa 1
- Familial adenomatous polyposis 0
- Nasopharyngeal carcinoma 255 open
- Oesophageal squamous cell carcinoma 102 open
- Hepatocellular carcinoma 6610 open
- Stomach cancer 115 open
- Lung cancer 362 open
- Pancreatic cancer 34
- Breast cancer 13548 open
- Glioma 11
- Hepatoblastoma 2
- Osteosarcoma 6
- Gastrointestinal stromal tumour 0
- Neuroblastoma 101 open
- Ewing sarcoma 2
- Multiple myeloma 1
- B-cell acute lymphoblastic leukaemia 4
- Haemophagocytic lymphohistiocytosis 4
- Lymphoma 7
- Beta thalassaemia 6
- Neuromyelitis optica spectrum disorder 01 open
- IgG4-related disease 4
- Coronary heart disease 29
- Congenital heart disease 2
- Scoliosis 4
- Hepatic echinococcosis 1
- Amyotrophic lateral sclerosis 3
- Behçet disease 1
- IgA nephropathy 7
- Osteogenesis imperfecta 0
- Primary biliary cholangitis 0
- Primary sclerosing cholangitis 0
- Nasopharyngeal carcinoma 48357 open
- Oesophageal squamous cell carcinoma 1378 open
- Hepatocellular carcinoma 28118 open
- Stomach cancer 1034 open
- Lung cancer 35732 open
- Pancreatic cancer 553 open
- Breast cancer 22217 open
- Glioma 621 open
- Hepatoblastoma 01 open
- Chordoma 0
- Osteosarcoma 191 open
- Gastrointestinal stromal tumour 2
- Neuroblastoma 75 open
- Ewing sarcoma 31 open
- Multiple myeloma 16
- B-cell acute lymphoblastic leukaemia 3
- Haemophagocytic lymphohistiocytosis 1
- Lymphoma 14225 open
- Beta thalassaemia 1
- Fanconi anaemia 0
- Idiopathic pulmonary fibrosis 2
- Nasopharyngeal carcinoma 10
- Hepatocellular carcinoma 1713 open
- Stomach cancer 15
- Pancreatic cancer 6
- Breast cancer 19
- Hepatoblastoma 1
- Osteosarcoma 2
- Gastrointestinal stromal tumour 0
- Neuroblastoma 1
- Multiple myeloma 4
- Haemophagocytic lymphohistiocytosis 1
- Lymphoma 6
- Beta thalassaemia 0
- Fanconi anaemia 1
- Neuromyelitis optica spectrum disorder 392 open
- Myasthenia gravis 01 open
- Moyamoya disease 3
- Wilson disease 0
- Coronary heart disease 9
- Scoliosis 4
- Anti-NMDA receptor encephalitis 22
- Takayasu arteritis 2
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 2
- Behçet disease 0
- Alport syndrome 1
- IgA nephropathy 0
- Niemann–Pick disease type C 0
- Primary biliary cholangitis 2
- Primary sclerosing cholangitis 1
- Hereditary angioedema 0
- Nasopharyngeal carcinoma 11
- Oesophageal squamous cell carcinoma 4
- Hepatocellular carcinoma 545 open
- Stomach cancer 10
- Lung cancer 691 open
- Pancreatic cancer 21
- Breast cancer 24
- Glioma 661 open
- Retinoblastoma 1
- Chordoma 1
- Osteosarcoma 9
- Neuroblastoma 6
- Multiple myeloma 23 open
- B-cell acute lymphoblastic leukaemia 12 open
- Lymphoma 101 open
- Beta thalassaemia 1
- Coronary heart disease 7
- Amyotrophic lateral sclerosis 1
- IgA nephropathy 2
- Hirschsprung disease 5
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for lymphoma.
Counts are listed hospitals only, not every hospital in each city.
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Guangzhou on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.